ERBB2 and breast cancer: Unsurprisingly, rates of reporting for ER, PR and human epidermal growth factor receptor-2 (HER2/neu) were the least recorded in this study, outlining the unavailability of immunohistochemistry in breast cancer management in Nigeria [19].